Skip to content
2000
Volume 22, Issue 13
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Given the lack of success in the development of effective drugs to treat COVID-19, which show “game-changing” potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is the case for direct antivirals and anti-inflammatory drugs, both of which treat different phases of the disease. Aptamers are molecules that deliver different modes of action, allowing their effects to be bundled, which, when combined, support their therapeutic efficacy. In this minireview, we summarise the current activities in the development of aptamers for the treatment of COVID-19 and long-COVID. A special emphasis is placed on the capability of their multiple modes of action, which is a promising approach for treating complex diseases such as COVID-19.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557522666220112094951
2022-07-01
2025-11-07
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557522666220112094951
Loading

  • Article Type:
    Review Article
Keyword(s): Aptamer; BC 007; COVID-19; long-COVID-19; multiple modes-of-action; SARS-CoV-2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test